

# Pharmacy Utilization Meeting

February 2, 2024

## Attendees

Linda Coyle (IMS)  
Jennifer Stevens (IMS)  
David Angelaszek (IMS)  
Emily Carver (IMS)  
Kevin Ward (Georgia)  
Randi Rycroft (Idaho)  
Serban Negoita (NCI)  
Peggy Adamo (NCI)  
Marina Matatova (NCI)  
Jennifer Hafterson (Seattle)  
Tiffany Janes (Seattle)  
Kaitlin Akif (NCI)  
Kathy Cronin (NCI)  
Nadia Howlader (NCI) – absent  
Steve Scoppa (IMS)  
Gretchen Flynn (IMS) – absent

- The meeting was spent looking at the SEER\*Stat datasets of the new pharmacy fields.
- Kathy Cronin and Serban both showed crosstabs of the Augmented/SEER Rx Summ Hormone field.
- Serban was looking at breast cases in 2019.
- Kathy Cronin's results looked at breast cases as well. She used a Research option that excluded registries such as NY, IL, TX, and ID. She used 2014-2021 (the Research option excluded 2022).
- There was some surprise that the percentage gain (augmented fields having better data than standard SEER fields) was at most ~5% in any registry. The group recalled that being better when examined before. Perhaps some of this is because of the 1-year timing rule for first course treatment.
- There were also some strange results where SEER had 01 and the augmented field had 00. David investigated and saw these were cases where the registry originally had the SEER field = 00 and there were no first course treatments linked to the patient. When the registry data was updated to 01 the polisher didn't change the augmented data to 01 - it stayed 00. David will investigate this and make a correction in the polisher.
- There were also a few strange cases where the augmented fields were 01 but the SEER fields indicate the patient didn't get treatment because the patient died. It was a single digit number of cases, but David will see if he can review those.
- Serban, Kathy and Kevin agreed that might be best to see coverage and value added in a cohort of ER+ female breast cases where oral hormone treatment is highly likely.

- Steve agreed to check Kathy's results to investigate if there were any configuration issues with the results.
- There was also concern about registries having differences in quality of results and whether looking at all registries combined will lead to misleading conclusions. There was a question if Kaiser data was being included in SE. David confirmed that it was.